• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Dapagliflozin in Patients with Chronic Kidney Disease. Reply.

作者信息

Heerspink Hiddo J L, Langkilde Anna-Maria, Wheeler David C

机构信息

University of Groningen, Groningen, the Netherlands

AstraZeneca, Gothenburg, Sweden.

出版信息

N Engl J Med. 2021 Jan 28;384(4):389-390. doi: 10.1056/NEJMc2032809.

DOI:10.1056/NEJMc2032809
PMID:33503362
Abstract
摘要

相似文献

1
Dapagliflozin in Patients with Chronic Kidney Disease. Reply.达格列净用于慢性肾脏病患者。回复
N Engl J Med. 2021 Jan 28;384(4):389-390. doi: 10.1056/NEJMc2032809.
2
The Authors' Reply to "How to Demonstrate the Impact of Dapagliflozin on Improving Hyperuricemia in Patients with Chronic Kidney Disease".作者对《如何证明达格列净对改善慢性肾脏病患者高尿酸血症的影响》的回复
Intern Med. 2024 Aug 1;63(15):2229-2230. doi: 10.2169/internalmedicine.3074-23. Epub 2024 Jan 2.
3
Effect of Dapagliflozin on Clinical Outcomes in Patients With Chronic Kidney Disease, With and Without Cardiovascular Disease.达格列净对伴有或不伴有心血管疾病的慢性肾脏病患者临床结局的影响。
Circulation. 2021 Feb 2;143(5):438-448. doi: 10.1161/CIRCULATIONAHA.120.051675. Epub 2020 Nov 13.
4
In brief: Dapagliflozin (Farxiga) for chronic kidney disease.简而言之：达格列净（安达唐）用于慢性肾病。
Med Lett Drugs Ther. 2021 Jul 26;63(1629):115.
5
Dapagliflozin in Patients with Chronic Kidney Disease.达格列净用于慢性肾脏病患者
N Engl J Med. 2021 Jan 28;384(4):389. doi: 10.1056/NEJMc2032809.
6
Dapagliflozin in Patients with Chronic Kidney Disease.达格列净用于慢性肾脏病患者
N Engl J Med. 2021 Jan 28;384(4):388-389. doi: 10.1056/NEJMc2032809.
7
Effects of Dapagliflozin on Hospitalizations in Patients With Chronic Kidney Disease.达格列净对慢性肾脏病患者住院治疗的影响。
Ann Intern Med. 2023 Jul;176(7):eL230069. doi: 10.7326/L23-0069.
8
Effects of Dapagliflozin on Hospitalizations in Patients With Chronic Kidney Disease.达格列净对慢性肾脏病患者住院治疗的影响。
Ann Intern Med. 2023 Jul;176(7):eL230070. doi: 10.7326/L23-0070.
9
Effects of dapagliflozin on major adverse kidney and cardiovascular events in patients with diabetic and non-diabetic chronic kidney disease: a prespecified analysis from the DAPA-CKD trial.达格列净对伴有和不伴有糖尿病的慢性肾脏病患者的主要不良肾脏和心血管事件的影响：来自 DAPA-CKD 试验的预先指定分析。
Lancet Diabetes Endocrinol. 2021 Jan;9(1):22-31. doi: 10.1016/S2213-8587(20)30369-7.
10
Dapagliflozin, advanced chronic kidney disease, and mortality: new insights from the DAPA-CKD trial.达格列净、晚期慢性肾脏病与死亡率：DAPA-CKD试验的新见解
Eur Heart J. 2021 Mar 31;42(13):1228-1230. doi: 10.1093/eurheartj/ehab092.

引用本文的文献

1
Effect of Pharmacogenetics on Renal Outcomes of Heart Failure Patients with Reduced Ejection Fraction (HFrEF) in Response to Dapagliflozin.药物遗传学对射血分数降低的心力衰竭（HFrEF）患者使用达格列净治疗后肾脏结局的影响。
Pharmaceutics. 2025 Jul 24;17(8):959. doi: 10.3390/pharmaceutics17080959.
2
Dapagliflozin and metabolic dysfunction-associated steatohepatitis.达格列净与代谢功能障碍相关脂肪性肝炎
BMJ. 2025 Jun 4;389:r1101. doi: 10.1136/bmj.r1101.
3
The effect of ertugliflozin in patients with nonalcoholic fatty liver disease associated with type 2 diabetes mellitus: A randomized controlled trial.
在伴有 2 型糖尿病的非酒精性脂肪性肝病患者中，厄格列净的疗效：一项随机对照试验。
Medicine (Baltimore). 2024 Nov 8;103(45):e40356. doi: 10.1097/MD.0000000000040356.
4
Biomarkers of Arginine Methylation in Diabetic Nephropathy: Novel Insights from Bioinformatics Analysis.糖尿病肾病中精氨酸甲基化的生物标志物：来自生物信息学分析的新见解
Diabetes Metab Syndr Obes. 2024 Sep 13;17:3399-3418. doi: 10.2147/DMSO.S472412. eCollection 2024.
5
Impact of Dapagliflozin Adjunctive Therapy on the Progression of Chronic Kidney Disease in Patients with Type 2 Diabetes and Chronic Kidney Disease Stages 2-5: A systematic review and meta-analysis.达格列净辅助治疗对 2 型糖尿病合并慢性肾脏病 2-5 期患者慢性肾脏病进展的影响：系统评价和荟萃分析。
Sultan Qaboos Univ Med J. 2024 Aug;24(3):317-326. doi: 10.18295/squmj.12.2023.093. Epub 2024 Aug 29.
6
Treatment of membranous nephropathy: Perspectives on current and future therapies.膜性肾病的治疗：当前及未来治疗方法的展望
Front Nephrol. 2023 Jan 27;3:1110355. doi: 10.3389/fneph.2023.1110355. eCollection 2023.
7
The sodium glucose co-transporter 2 inhibitor dapagliflozin ameliorates the fluid-retaining effect of the endothelin A receptor antagonist zibotentan.钠-葡萄糖协同转运蛋白 2 抑制剂达格列净可改善内皮素 A 受体拮抗剂西他生坦的保水作用。
Nephrol Dial Transplant. 2023 Sep 29;38(10):2289-2297. doi: 10.1093/ndt/gfad078.
8
What's New in the Molecular Mechanisms of Diabetic Kidney Disease: Recent Advances.糖尿病肾病的分子机制有哪些新进展：最新研究进展。
Int J Mol Sci. 2022 Dec 29;24(1):570. doi: 10.3390/ijms24010570.
9
Developing a contemporary community clinic for patients with heart failure with preserved ejection fraction within the current National Health Service model.在当前的国民保健制度模式下，为射血分数保留的心力衰竭患者开发一个现代化的社区诊所。
Open Heart. 2022 Nov;9(2). doi: 10.1136/openhrt-2022-002101.
10
Non-invasive molecular imaging of kidney diseases.肾脏疾病的无创分子影像学。
Nat Rev Nephrol. 2021 Oct;17(10):688-703. doi: 10.1038/s41581-021-00440-4. Epub 2021 Jun 29.